Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Purpose

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Conditions

  • Endometrial Carcinoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Dedifferentiated Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Uterine Corpus Carcinosarcoma

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial cancer. The following endometrial cancer types are eligible: - Serous - Other endometrial cancers (including clear cell, endometrioid, mixed epithelial, dedifferentiated/undifferentiated) - Carcinosarcoma - NOTE: Endometrial cancers that are mismatch repair deficient (dMMR) by IHC are not eligible - Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required - Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration - Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI - For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded - All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines (https://documents.cap.org/documents/algorithim-evaluation-her2.pdf.) IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. In general HER2 positivity is defined as any of the following: - 3+ immunohistochemistry (IHC), - 2+ IHC with positive in situ hybridization (ISH) Alternatively, patients could be eligible if next generation sequencing (NGS) demonstrates HER2 (ERBB2) amplification. NGS testing can be performed through any designated labs as per the National Cancer Institute (NCI) MATCH/NCI Combo-MATCH trial (https://ecog-acrin.org/nci-match-eay131-designated-labs). Pathology report showing results of institutional HER2 testing (or NGS testing results) must be submitted. Sites must submit all results available (IHC, ISH, and NGS) - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - Age >= 18 - Platelets >= 100,000/mcl (within 14 days prior to registration) - Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration) - Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN) or estimated Glomerular filtration rate (eGFR) >= 50 mL/min using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR) (within 14 days prior to registration) - Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to registration) - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial - Although the uterus will have been removed in the vast majority of patients, for patients of child-bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Patients will be considered of non-reproductive potential if they are either: - Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR - Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to registration - Have a congenital or acquired condition that prevents childbearing - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria

  • Prior Therapy: - Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma - Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy - NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration - Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration - Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration - Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration - Significant cardiovascular disease including: - Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg despite antihypertensive medications - Myocardial infarction or unstable angina within 6 months prior to registration - New York Heart Association functional classification II, III or IV - Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate - Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia) - Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), uncontrolled interstitial lung disease, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements - Treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to registration - Women who are unwilling to discontinue nursing

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Arm I (paclitaxel, carboplatin) 		Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
  • Procedure: Biospecimen Collection
    Undergo blood and urine sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Drug: Carboplatin
    Given IV
    Other names:
    • Blastocarb
    • Carboplat
    • Carboplatin Hexal
    • Carboplatino
    • Carboplatinum
    • Carbosin
    • Carbosol
    • Carbotec
    • CBDCA
    • Displata
    • Ercar
    • JM-8
    • JM8
    • Nealorin
    • Novoplatinum
    • Paraplatin
    • Paraplatin AQ
    • Paraplatine
    • Platinwas
    • Ribocarbo
  • Procedure: Computed Tomography
    Undergo CT
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • Computerized Tomography (CT) scan
    • CT
    • CT Scan
    • Diagnostic CAT Scan
    • Diagnostic CAT Scan Service Type
    • tomography
  • Procedure: Echocardiography Test
    Undergo ECHO
    Other names:
    • EC
    • Echocardiography
  • Radiation: High-Dose-Rate Vaginal Cuff Brachytherapy
    Undergo vaginal brachytherapy
    Other names:
    • HDR-VCB
  • Procedure: Multigated Acquisition Scan
    Undergo MUGA
    Other names:
    • Blood Pool Scan
    • Equilibrium Radionuclide Angiography
    • Gated Blood Pool Imaging
    • MUGA
    • Radionuclide Ventriculography
    • RNVG
    • SYMA Scanning
    • Synchronized Multigated Acquisition Scanning
  • Drug: Paclitaxel
    Given IV
    Other names:
    • Anzatax
    • Asotax
    • Bristaxol
    • Praxel
    • Taxol
    • Taxol Konzentrat
Experimental
Arm II (paclitaxel, carboplatin, Herceptin Hylecta) 		Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment. Patients undergo ECHO or MUGA and CT throughout the study. Additionally patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
  • Procedure: Biospecimen Collection
    Undergo blood and urine sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Drug: Carboplatin
    Given IV
    Other names:
    • Blastocarb
    • Carboplat
    • Carboplatin Hexal
    • Carboplatino
    • Carboplatinum
    • Carbosin
    • Carbosol
    • Carbotec
    • CBDCA
    • Displata
    • Ercar
    • JM-8
    • JM8
    • Nealorin
    • Novoplatinum
    • Paraplatin
    • Paraplatin AQ
    • Paraplatine
    • Platinwas
    • Ribocarbo
  • Procedure: Computed Tomography
    Undergo CT
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • Computerized Tomography (CT) scan
    • CT
    • CT Scan
    • Diagnostic CAT Scan
    • Diagnostic CAT Scan Service Type
    • tomography
  • Procedure: Echocardiography Test
    Undergo ECHO
    Other names:
    • EC
    • Echocardiography
  • Radiation: High-Dose-Rate Vaginal Cuff Brachytherapy
    Undergo vaginal brachytherapy
    Other names:
    • HDR-VCB
  • Procedure: Multigated Acquisition Scan
    Undergo MUGA
    Other names:
    • Blood Pool Scan
    • Equilibrium Radionuclide Angiography
    • Gated Blood Pool Imaging
    • MUGA
    • Radionuclide Ventriculography
    • RNVG
    • SYMA Scanning
    • Synchronized Multigated Acquisition Scanning
  • Drug: Paclitaxel
    Given IV
    Other names:
    • Anzatax
    • Asotax
    • Bristaxol
    • Praxel
    • Taxol
    • Taxol Konzentrat
  • Other: Survey Administration
    Ancillary studies
  • Drug: Trastuzumab/Hyaluronidase-oysk
    Given SC
    Other names:
    • Herceptin Hylecta
    • Trastuzumab and Hyaluronidase
    • Trastuzumab and Hyaluronidase-oysk
    • Trastuzumab and Recombinant Human Hyaluronidase PH20
    • Trastuzumab and rHuPH20
    • Trastuzumab-Hyaluronidase-oysk
Experimental
Arm III (paclitaxel, carboplatin, Phesgo) 		Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment. Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
  • Procedure: Biospecimen Collection
    Undergo blood and urine sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Drug: Carboplatin
    Given IV
    Other names:
    • Blastocarb
    • Carboplat
    • Carboplatin Hexal
    • Carboplatino
    • Carboplatinum
    • Carbosin
    • Carbosol
    • Carbotec
    • CBDCA
    • Displata
    • Ercar
    • JM-8
    • JM8
    • Nealorin
    • Novoplatinum
    • Paraplatin
    • Paraplatin AQ
    • Paraplatine
    • Platinwas
    • Ribocarbo
  • Procedure: Computed Tomography
    Undergo CT
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • Computerized Tomography (CT) scan
    • CT
    • CT Scan
    • Diagnostic CAT Scan
    • Diagnostic CAT Scan Service Type
    • tomography
  • Procedure: Echocardiography Test
    Undergo ECHO
    Other names:
    • EC
    • Echocardiography
  • Radiation: High-Dose-Rate Vaginal Cuff Brachytherapy
    Undergo vaginal brachytherapy
    Other names:
    • HDR-VCB
  • Drug: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
    Given SC
    Other names:
    • Pertuzumab and Trastuzumab hyaluronidase
    • Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
    • Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
    • Phesgo
  • Procedure: Multigated Acquisition Scan
    Undergo MUGA
    Other names:
    • Blood Pool Scan
    • Equilibrium Radionuclide Angiography
    • Gated Blood Pool Imaging
    • MUGA
    • Radionuclide Ventriculography
    • RNVG
    • SYMA Scanning
    • Synchronized Multigated Acquisition Scanning
  • Drug: Paclitaxel
    Given IV
    Other names:
    • Anzatax
    • Asotax
    • Bristaxol
    • Praxel
    • Taxol
    • Taxol Konzentrat
  • Other: Survey Administration
    Ancillary studies

Recruiting Locations

University of Alabama at Birmingham Cancer Center
Birmingham 4049979, Alabama 4829764 35233
Contact:
Site Public Contact
205-934-0220
tmyrick@uab.edu

Alaska Women's Cancer Care
Anchorage 5879400, Alaska 5879092 99508
Contact:
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Banner University Medical Center - Tucson
Tucson 5318313, Arizona 5551752 85719
Contact:
Site Public Contact
UACC-IIT@uacc.arizona.edu

University of Arizona Cancer Center-North Campus
Tucson 5318313, Arizona 5551752 85719
Contact:
Site Public Contact
UACC-IIT@uacc.arizona.edu

University of Arkansas for Medical Sciences
Little Rock 4119403, Arkansas 4099753 72205
Contact:
Site Public Contact
501-686-8274

Sutter Auburn Faith Hospital
Auburn 5325223, California 5332921 95602
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Alta Bates Summit Medical Center-Herrick Campus
Berkeley 5327684, California 5332921 94704
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Irvine
Irvine 5359777, California 5332921 92618
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente Los Angeles Medical Center
Los Angeles 5368361, California 5332921 90027
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Memorial Medical Center
Modesto 5373900, California 5332921 95355
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View 5375480, California 5332921 94040
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Saint Joseph Hospital - Orange
Orange 5379513, California 5332921 92868
Contact:
Site Public Contact
714-734-6220

Stanford Cancer Institute Palo Alto
Palo Alto 5380748, California 5332921 94304
Contact:
Site Public Contact
650-498-7061
ccto-office@stanford.edu

Kaiser Permanente - Panorama City
Panorama City 5380932, California 5332921 91402
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Riverside
Riverside 5387877, California 5332921 92505
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Sutter Roseville Medical Center
Roseville 5388881, California 5332921 95661
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Medical Center Sacramento
Sacramento 5389489, California 5332921 95816
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

University of California Davis Comprehensive Cancer Center
Sacramento 5389489, California 5332921 95817
Contact:
Site Public Contact
916-734-3089

California Pacific Medical Center-Pacific Campus
San Francisco 5391959, California 5332921 94115
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Palo Alto Medical Foundation-Santa Cruz
Santa Cruz 5393052, California 5332921 95065
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Palo Alto Medical Foundation-Sunnyvale
Sunnyvale 5400075, California 5332921 94086
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

John Muir Medical Center-Walnut Creek
Walnut Creek 5406990, California 5332921 94598
Contact:
Site Public Contact
925-941-4246
clinicalresearch@johnmuirhealth.com

UCHealth University of Colorado Hospital
Aurora 5412347, Colorado 5417618 80045
Contact:
Site Public Contact
720-848-0650

UCHealth - Cherry Creek
Denver 5419384, Colorado 5417618 80206
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

AdventHealth Porter
Denver 5419384, Colorado 5417618 80210
Contact:
Site Public Contact
research.institute@adventhealth.com

Grand Valley Oncology
Grand Junction 5423573, Colorado 5417618 81505
Contact:
Site Public Contact
970-644-4460
gvoclinicaltrials@gjhosp.org

Banner North Colorado Medical Center
Greeley 5577592, Colorado 5417618 80631
Contact:
Site Public Contact
970-810-3046
BMDACCResearchCOMailbox@bannerhealth.com

UCHealth Highlands Ranch Hospital
Highlands Ranch 5425043, Colorado 5417618 80129
Contact:
Site Public Contact
720-848-0650

Banner McKee Medical Center
Loveland 5579368, Colorado 5417618 80539
Contact:
Site Public Contact
970-810-3046
BMDACCResearchCOMailbox@bannerhealth.com

Danbury Hospital
Danbury 4832353, Connecticut 4831725 06810
Contact:
Site Public Contact
203-739-8074

Smilow Cancer Hospital-Derby Care Center
Derby 4832745, Connecticut 4831725 06418
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Fairfield
Fairfield 4834157, Connecticut 4831725 06824
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury 4835003, Connecticut 4831725 06033
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Greenwich
Greenwich 4835395, Connecticut 4831725 06830
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Guilford
Guilford 4835512, Connecticut 4831725 06437
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Saint Francis
Hartford 4835797, Connecticut 4831725 06105
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale University
New Haven 4839366, Connecticut 4831725 06520
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale-New Haven Hospital North Haven Medical Center
North Haven 4839704, Connecticut 4831725 06473
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Norwalk Hospital
Norwalk 4839822, Connecticut 4831725 06856
Contact:
Site Public Contact
203-852-2996
jennifer.long@norwalkhealth.org

Smilow Cancer Hospital Care Center at Long Ridge
Stamford 4843564, Connecticut 4831725 06902
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Torrington Care Center
Torrington 4844309, Connecticut 4831725 06790
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Trumbull
Trumbull 4844459, Connecticut 4831725 06611
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Waterbury Care Center
Waterbury 4845193, Connecticut 4831725 06708
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Waterford
Waterford 8480031, Connecticut 4831725 06385
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Helen F Graham Cancer Center
Newark 4143861, Delaware 4142224 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Medical Oncology Hematology Consultants PA
Newark 4143861, Delaware 4142224 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Sibley Memorial Hospital
Washington D.C. 4140963, District of Columbia 4138106 20016
Contact:
Site Public Contact
202-243-2373
jquiver1@jhmi.edu

George Washington University Medical Center
Washington D.C. 4140963, District of Columbia 4138106 20037
Contact:
Site Public Contact
202-741-2210

Broward Health Medical Center
Fort Lauderdale 4155966, Florida 4155751 33316
Contact:
Site Public Contact
302-651-5572
Allison.bruce@nemours.org

Sarasota Memorial Hospital-Venice
N. Venice, Florida 4155751 34275
Contact:
Site Public Contact
941-261-9000

AdventHealth Orlando
Orlando 4167147, Florida 4155751 32803
Contact:
Site Public Contact
407-303-2090
FH.Cancer.Research@flhosp.org

Florida Cancer Specialists - Sarasota Downtown
Sarasota 4172131, Florida 4155751 34236
Contact:
Site Public Contact
941-957-1000

First Physicians Group-Sarasota
Sarasota 4172131, Florida 4155751 34239
Contact:
Site Public Contact
941-917-8383

Sarasota Memorial Hospital
Sarasota 4172131, Florida 4155751 34239
Contact:
Site Public Contact
941-917-2225

Florida Cancer Specialists - Venice Pinebrook
Venice 4176380, Florida 4155751 34275
Contact:
Site Public Contact
239-274-9930
ClinicalTrials@FLCancer.com

Grady Health System
Atlanta 4180439, Georgia 4197000 30303
Contact:
Site Public Contact
404-778-1868

Emory University Hospital Midtown
Atlanta 4180439, Georgia 4197000 30308
Contact:
Site Public Contact
888-946-7447

Piedmont Hospital
Atlanta 4180439, Georgia 4197000 30309
Contact:
Site Public Contact
404-425-7943
ORS@piedmont.org

Emory University Hospital/Winship Cancer Institute
Atlanta 4180439, Georgia 4197000 30322
Contact:
Site Public Contact
404-778-1868

Emory Saint Joseph's Hospital
Atlanta 4180439, Georgia 4197000 30342
Contact:
Site Public Contact
404-851-7115

Augusta University Medical Center
Augusta 4180531, Georgia 4197000 30912
Contact:
Site Public Contact
706-721-2388
ga_cares@augusta.edu

Emory Decatur Hospital
Decatur 4191124, Georgia 4197000 30033
Contact:
Site Public Contact
440-778-1868
clinicaltrialsoncology@dekalbmedical.org

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah 4221552, Georgia 4197000 31405
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Queen's Medical Center
Honolulu 5856195, Hawaii 5855797 96813
Contact:
Site Public Contact
808-545-8548

Kapiolani Medical Center for Women and Children
Honolulu 5856195, Hawaii 5855797 96826
Contact:
Site Public Contact
808-983-6090

Saint Luke's Cancer Institute - Boise
Boise 5586437, Idaho 5596512 83712
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Kootenai Health - Coeur d'Alene
Coeur d'Alene 5589173, Idaho 5596512 83814
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Luke's Cancer Institute - Fruitland
Fruitland 5593708, Idaho 5596512 83619
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Meridian
Meridian 5600685, Idaho 5596512 83642
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Nampa
Nampa 5601933, Idaho 5596512 83687
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Kootenai Clinic Cancer Services - Post Falls
Post Falls 5604353, Idaho 5596512 83854
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kootenai Clinic Cancer Services - Sandpoint
Sandpoint 5606401, Idaho 5596512 83864
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Luke's Cancer Institute - Twin Falls
Twin Falls 5610810, Idaho 5596512 83301
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Northwest Community Hospital
Arlington Heights 4883555, Illinois 4896861 60005
Contact:
Site Public Contact
847-618-4968

Centralia Oncology Clinic
Centralia 4235587, Illinois 4896861 62801
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern University
Chicago 4887398, Illinois 4896861 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

John H Stroger Jr Hospital of Cook County
Chicago 4887398, Illinois 4896861 60612
Contact:
Site Public Contact
312-864-5204

University of Chicago Comprehensive Cancer Center
Chicago 4887398, Illinois 4896861 60637
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Carle at The Riverfront
Danville 4889426, Illinois 4896861 61832
Contact:
Site Public Contact
800-446-5532
Research@Carle.com

Cancer Care Specialists of Illinois - Decatur
Decatur 4236895, Illinois 4896861 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Decatur Memorial Hospital
Decatur 4236895, Illinois 4896861 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Kishwaukee
DeKalb 4889553, Illinois 4896861 60115
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Carle Physician Group-Effingham
Effingham 4237727, Illinois 4896861 62401
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Crossroads Cancer Center
Effingham 4237727, Illinois 4896861 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

NorthShore University HealthSystem-Evanston Hospital
Evanston 4891382, Illinois 4896861 60201
Contact:
Site Public Contact
847-570-2109

Northwestern Medicine Cancer Center Delnor
Geneva 4893591, Illinois 4896861 60134
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

NorthShore University HealthSystem-Glenbrook Hospital
Glenview 4893886, Illinois 4896861 60026
Contact:
Site Public Contact
847-570-2109

NorthShore University HealthSystem-Highland Park Hospital
Highland Park 4895876, Illinois 4896861 60035
Contact:
Site Public Contact
847-570-2109

Northwestern Medicine Lake Forest Hospital
Lake Forest 4899012, Illinois 4896861 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

Carle Physician Group-Mattoon/Charleston
Mattoon 4244099, Illinois 4896861 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

UC Comprehensive Cancer Center at Silver Cross
New Lenox 4903535, Illinois 4896861 60451
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Cancer Care Center of O'Fallon
O'Fallon 4245926, Illinois 4896861 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Orland Park
Orland Park 4904937, Illinois 4896861 60462
Contact:
Site Public Contact
nctnprogram_rhlccc@northwestern.edu

University of Chicago Medicine-Orland Park
Orland Park 4904937, Illinois 4896861 60462
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Southern Illinois University School of Medicine
Springfield 4250542, Illinois 4896861 62702
Contact:
Site Public Contact
217-545-7929

Springfield Clinic
Springfield 4250542, Illinois 4896861 62702
Contact:
Site Public Contact
800-444-7541

Springfield Memorial Hospital
Springfield 4250542, Illinois 4896861 62781
Contact:
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Carle Cancer Center
Urbana 4914570, Illinois 4896861 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville 4915525, Illinois 4896861 60555
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

IU Health North Hospital
Carmel 4255466, Indiana 4921868 46032
Contact:
Site Public Contact
317-278-5632
iutrials@iu.edu

Northwest Cancer Center - Main Campus
Crown Point 4919451, Indiana 4921868 46307
Contact:
Site Public Contact
219-310-2550

UChicago Medicine Northwest Indiana
Crown Point 4919451, Indiana 4921868 46307
Contact:
Site Public Contact
855-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Northwest Oncology LLC
Dyer 4919820, Indiana 4921868 46311
Contact:
Site Public Contact
219-924-8178

Goshen Center for Cancer Care
Goshen 4920808, Indiana 4921868 46526
Contact:
Site Public Contact
574-364-2973
cccois@goshenhealth.com

Northwest Cancer Center - Hobart
Hobart 4921476, Indiana 4921868 46342
Contact:
Site Public Contact
219-947-1795

Saint Mary Medical Center
Hobart 4921476, Indiana 4921868 46342
Contact:
Site Public Contact
219-836-6875
CancerResearch@COMHS.org

Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis 4259418, Indiana 4921868 46202
Contact:
Site Public Contact
317-278-5632
iutrials@iu.edu

Franciscan Health Indianapolis
Indianapolis 4259418, Indiana 4921868 46237
Contact:
Site Public Contact
317-528-7060

Saint Catherine Hospital
Indianapolis 4259418, Indiana 4921868 46312
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Franciscan Saint Elizabeth Health - Lafayette East
Lafayette 4922462, Indiana 4921868 47905
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Franciscan Health Mooresville
Mooresville 4261585, Indiana 4921868 46158
Contact:
Site Public Contact
317-834-3603

The Community Hospital
Munster 4924014, Indiana 4921868 46321
Contact:
Site Public Contact
219-836-3349

Women's Diagnostic Center - Munster
Munster 4924014, Indiana 4921868 46321
Contact:
Site Public Contact
219-934-8869
mnicholson@comhs.org

Northwest Cancer Center - Valparaiso
Valparaiso 4927537, Indiana 4921868 46383
Contact:
Site Public Contact
219-836-6875
CancerResearch@COMHS.org

Mary Greeley Medical Center
Ames 4846834, Iowa 4862182 50010
Contact:
Site Public Contact
515-956-4132

McFarland Clinic - Ames
Ames 4846834, Iowa 4862182 50010
Contact:
Site Public Contact
515-239-4734
ksoder@mcfarlandclinic.com

McFarland Clinic - Boone
Boone 4849051, Iowa 4862182 50036
Contact:
Site Public Contact
515-956-4132

Heartland Oncology and Hematology LLP
Council Bluffs 4852832, Iowa 4862182 51503
Contact:
Site Public Contact
712-322-4136

Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
Council Bluffs 4852832, Iowa 4862182 51503
Contact:
Site Public Contact
402-354-5892
Liza.brandes@nmhs.org

McFarland Clinic - Trinity Cancer Center
Fort Dodge 4857486, Iowa 4862182 50501
Contact:
Site Public Contact
515-956-4132

University of Iowa/Holden Comprehensive Cancer Center
Iowa City 4862034, Iowa 4862182 52242
Contact:
Site Public Contact
800-237-1225

McFarland Clinic - Jefferson
Jefferson 4862482, Iowa 4862182 50129
Contact:
Site Public Contact
515-956-4132

McFarland Clinic - Marshalltown
Marshalltown 4866371, Iowa 4862182 50158
Contact:
Site Public Contact
515-956-4132

Saint Elizabeth Healthcare Edgewood
Edgewood 4290873, Kentucky 6254925 41017
Contact:
Site Public Contact
859-301-4730
Kristi.Curtsinger@stelizabeth.com

Baptist Health Lexington
Lexington 4297983, Kentucky 6254925 40503
Contact:
Site Public Contact
859-260-6425

LSU Health Baton Rouge-North Clinic
Baton Rouge 4315588, Louisiana 4331987 70805
Contact:
Site Public Contact
225-765-7659
research@ololrmc.com

Our Lady of the Lake Physician Group
Baton Rouge 4315588, Louisiana 4331987 70808
Contact:
Site Public Contact
225-765-7659
research@ololrmc.com

Our Lady of the Lake Medical Oncology
Baton Rouge 4315588, Louisiana 4331987 70817
Contact:
Site Public Contact
225-765-7659
research@ololrmc.com

Ochsner Hematology Oncology North Shore - Covington (West Region)
Covington 4321005, Louisiana 4331987 70433
Contact:
Site Public Contact
985-809-5668
Cheryl.kesler@ochsner.org

West Jefferson Medical Center
Marrero 4332628, Louisiana 4331987 70072
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

East Jefferson General Hospital
Metairie 4333177, Louisiana 4331987 70006
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

University Medical Center New Orleans
New Orleans 4335045, Louisiana 4331987 70112
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

Ochsner Baptist Medical Center
New Orleans 4335045, Louisiana 4331987 70115
Contact:
Site Public Contact
504-842-8084
Elisemarie.curry@ochsner.org

Ochsner Medical Center Jefferson
New Orleans 4335045, Louisiana 4331987 70121
Contact:
Site Public Contact
504-842-8084
Elisemarie.curry@ochsner.org

Harold Alfond Center for Cancer Care
Augusta 4957003, Maine 4971068 04330
Contact:
Site Public Contact
207-626-4855

MaineHealth Maine Medical Center- Scarborough
Scarborough 4977882, Maine 4971068 04074
Contact:
Site Public Contact
207-396-8670
clinicalresearch@mainehealth.org

Greater Baltimore Medical Center
Baltimore 4347778, Maryland 4361885 21204
Contact:
Site Public Contact
443-849-3706

Sinai Hospital of Baltimore
Baltimore 4347778, Maryland 4361885 21215
Contact:
Site Public Contact
410-601-9083

MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Baltimore 4347778, Maryland 4361885 21237
Contact:
Site Public Contact
443-777-7364

Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore 4347778, Maryland 4361885 21287
Contact:
Site Public Contact
410-955-8804
jhcccro@jhmi.edu

Walter Reed National Military Medical Center
Bethesda 4348599, Maryland 4361885 20889-5600
Contact:
Site Public Contact
301-319-2100

William E Kahlert Regional Cancer Center/Sinai Hospital
Westminster 4373238, Maryland 4361885 21157
Contact:
Site Public Contact
410-871-6400

Baystate Medical Center
Springfield 4951788, Massachusetts 6254926 01199
Contact:
Site Public Contact
413-794-3565
tamara.wrenn@baystatehealth.org

University of Michigan Comprehensive Cancer Center
Ann Arbor 4984247, Michigan 5001836 48109
Contact:
Site Public Contact
slusserb@med.umich.edu

Bronson Battle Creek
Battle Creek 4985153, Michigan 5001836 49017
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton 4986994, Michigan 5001836 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton 4987990, Michigan 5001836 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea 4988628, Michigan 5001836 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Wayne State University/Karmanos Cancer Institute
Detroit 4990729, Michigan 5001836 48201
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Weisberg Cancer Treatment Center
Farmington Hills 4992523, Michigan 5001836 48334
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Cancer Hematology Centers - Flint
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Genesys Hurley Cancer Institute
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Hurley Medical Center
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids 4994358, Michigan 5001836 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health Grand Rapids Hospital
Grand Rapids 4994358, Michigan 5001836 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Bronson Methodist Hospital
Kalamazoo 4997787, Michigan 5001836 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Kalamazoo 4997787, Michigan 5001836 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Beacon Kalamazoo Cancer Center
Kalamazoo 4997787, Michigan 5001836 49009
Contact:
Site Public Contact
574-647-7370

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia 4999837, Michigan 5001836 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Muskegon Hospital
Muskegon 5003132, Michigan 5001836 49444
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Corewell Health Lakeland Hospitals - Niles Hospital
Niles 5003514, Michigan 5001836 49120
Contact:
Site Public Contact
616-391-1230

Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores 5004005, Michigan 5001836 49444
Contact:
Site Public Contact
616-391-1230
connie.szczepanek@crcwm.org

Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac 5006166, Michigan 5001836 48341
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Corewell Health Reed City Hospital
Reed City 5006946, Michigan 5001836 49677
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

MyMichigan Medical Center Saginaw
Saginaw 5007989, Michigan 5001836 48601
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Saint Joseph 5008327, Michigan 5001836 49085
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Saint Joseph 5008327, Michigan 5001836 49085
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

MyMichigan Medical Center Tawas
Tawas City 5011900, Michigan 5001836 48764
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Munson Medical Center
Traverse City 5012495, Michigan 5001836 49684
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

University of Michigan Health - West
Wyoming 5015618, Michigan 5001836 49519
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti 5015688, Michigan 5001836 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Mercy Hospital
Coon Rapids 5022025, Minnesota 5037779 55433
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Fairview Southdale Hospital
Edina 5025264, Minnesota 5037779 55435
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Minnesota Oncology Hematology PA-Maplewood
Maplewood 5036588, Minnesota 5037779 55109
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Abbott-Northwestern Hospital
Minneapolis 5037649, Minnesota 5037779 55407
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

University of Minnesota/Masonic Cancer Center
Minneapolis 5037649, Minnesota 5037779 55455
Contact:
Site Public Contact
612-624-2620

Park Nicollet Clinic - Saint Louis Park
Saint Louis Park 5045021, Minnesota 5037779 55416
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Regions Hospital
Saint Paul 5045360, Minnesota 5037779 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

United Hospital
Saint Paul 5045360, Minnesota 5037779 55102
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Minnesota Oncology Hematology PA-Woodbury
Woodbury 5053358, Minnesota 5037779 55125
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia 4381982, Missouri 4398678 65212
Contact:
Site Public Contact
573-882-7440

Phelps Health Delbert Day Cancer Institute
Rolla 4406282, Missouri 4398678 65401
Contact:
Site Public Contact
573-458-7504
research@phelpshealth.org

CoxHealth South Hospital
Springfield 4409896, Missouri 4398678 65807
Contact:
Site Public Contact
417-269-4520

Washington University School of Medicine
St Louis 4407066, Missouri 4398678 63110
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Mercy Hospital South
St Louis 4407066, Missouri 4398678 63128
Contact:
Site Public Contact
314-525-6042
Danielle.Werle@mercy.net

Mercy Hospital Saint Louis
St Louis 4407066, Missouri 4398678 63141
Contact:
Site Public Contact
314-251-7066

Community Hospital of Anaconda
Anaconda 5637146, Montana 5667009 59711
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Billings Clinic Cancer Center
Billings 5640350, Montana 5667009 59101
Contact:
Site Public Contact
800-996-2663
research@billingsclinic.org

Saint Vincent Frontier Cancer Center
Billings 5640350, Montana 5667009 59102
Contact:
Site Public Contact
800-648-6274

Intermountain Health West End Clinic
Billings 5640350, Montana 5667009 59106
Contact:
Site Public Contact
406-238-6685

Bozeman Health Deaconess Hospital
Bozeman 5641727, Montana 5667009 59715
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Benefis Sletten Cancer Institute
Great Falls 5655240, Montana 5667009 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Logan Health Medical Center
Kalispell 5660340, Montana 5667009 59901
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Patrick Hospital - Community Hospital
Missoula 5666639, Montana 5667009 59802
Contact:
Site Public Contact
406-327-3118
amy.hanneman@providence.org

Community Medical Center
Missoula 5666639, Montana 5667009 59804
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
Omaha 5074472, Nebraska 5073708 68114
Contact:
Site Public Contact
402-334-4773

Nebraska Methodist Hospital
Omaha 5074472, Nebraska 5073708 68114
Contact:
Site Public Contact
402-354-5144

Alegent Health Bergan Mercy Medical Center
Omaha 5074472, Nebraska 5073708 68124
Contact:
Site Public Contact
720-874-1881
ResearchInstituteInquiries@CommonSpirit.org

University of Nebraska Medical Center
Omaha 5074472, Nebraska 5073708 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

OptumCare Cancer Care at Seven Hills
Henderson 5505411, Nevada 5509151 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Charleston
Las Vegas 5506956, Nevada 5509151 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Women's Cancer Center of Nevada
Las Vegas 5506956, Nevada 5509151 89106
Contact:
Site Public Contact
702-851-4672

OptumCare Cancer Care at Fort Apache
Las Vegas 5506956, Nevada 5509151 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Memorial Sloan Kettering Basking Ridge
Basking Ridge 5095409, New Jersey 5101760 07920
Contact:
Site Public Contact
212-639-7592

Cooper Hospital University Medical Center
Camden 4501018, New Jersey 5101760 08103
Contact:
Site Public Contact
856-325-6757

Hackensack University Medical Center
Hackensack 5098706, New Jersey 5101760 07601
Contact:
Site Public Contact
551-996-2897

Monmouth Medical Center Southern Campus
Lakewood 5100280, New Jersey 5101760 08701
Contact:
Site Public Contact
732-923-6564
mary.danish@rwjbh.org

Saint Barnabas Medical Center
Livingston 5100572, New Jersey 5101760 07039
Contact:
Site Public Contact
973-322-2934
joanne.loeb@rwjbh.org

Monmouth Medical Center
Long Branch 5100619, New Jersey 5101760 07740
Contact:
Site Public Contact
732-923-6564
mary.danish@rwjbh.org

Memorial Sloan Kettering Monmouth
Middletown 5101170, New Jersey 5101760 07748
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Bergen
Montvale 5101361, New Jersey 5101760 07645
Contact:
Site Public Contact
212-639-7592

Jersey Shore Medical Center
Neptune City 5101687, New Jersey 5101760 07753
Contact:
Site Public Contact
732-776-4240

Rutgers Cancer Institute of New Jersey
New Brunswick 5101717, New Jersey 5101760 08903
Contact:
Site Public Contact
732-235-7356

Riverview Medical Center/Booker Cancer Center
Red Bank 5103159, New Jersey 5101760 07701
Contact:
Site Public Contact
732-530-2382

Sidney Kimmel Cancer Center Washington Township
Sewell 4504048, New Jersey 5101760 08080
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Robert Wood Johnson University Hospital Somerset
Somerville 5104774, New Jersey 5101760 08876
Contact:
Site Public Contact
908-685-2481
Siby.Varughese@rwjbh.org

Community Medical Center
Toms River 4504476, New Jersey 5101760 08755
Contact:
Site Public Contact
732-557-8294
Lennette.Gonzales@rwjbh.org

University of New Mexico Cancer Center
Albuquerque 5454711, New Mexico 5481136 87106
Contact:
Site Public Contact
505-925-0348
HSC-ClinicalTrialInfo@salud.unm.edu

Women's Cancer Care Associates LLC
Albany 5106834, New York 5128638 12208
Contact:
Site Public Contact
518-458-1390
jbarlin@womenscancercareassociates.com

Memorial Sloan Kettering Commack
Commack 5113412, New York 5128638 11725
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Westchester
Harrison 5120095, New York 5128638 10604
Contact:
Site Public Contact
212-639-7592

NYU Langone Hospital - Long Island
Mineola 5127134, New York 5128638 11501
Contact:
Site Public Contact
212-263-4432
cancertrials@nyulangone.org

Mount Sinai Chelsea
New York 5128581, New York 5128638 10011
Contact:
Site Public Contact
212-824-7309
CCTO@mssm.edu

Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York 5128581, New York 5128638 10016
Contact:
Site Public Contact
CancerTrials@nyulangone.org

Mount Sinai Hospital
New York 5128581, New York 5128638 10029
Contact:
Site Public Contact
212-824-7309
CCTO@mssm.edu

Memorial Sloan Kettering Cancer Center
New York 5128581, New York 5128638 10065
Contact:
Site Public Contact
212-639-7592

University of Rochester
Rochester 5134086, New York 5128638 14642
Contact:
Site Public Contact
585-275-5830

State University of New York Upstate Medical University
Syracuse 5140405, New York 5128638 13210
Contact:
Site Public Contact
315-464-5476

Memorial Sloan Kettering Nassau
Uniondale 5141927, New York 5128638 11553
Contact:
Site Public Contact
212-639-7592

Duke Cancer Center Cary
Cary 4459467, North Carolina 4482348 27518
Contact:
Site Public Contact
NCTNStudyTeam@dm.duke.edu

UNC Lineberger Comprehensive Cancer Center
Chapel Hill 4460162, North Carolina 4482348 27599
Contact:
Site Public Contact
877-668-0683
cancerclinicaltrials@med.unc.edu

Duke University Medical Center
Durham 4464368, North Carolina 4482348 27710
Contact:
Site Public Contact
888-275-3853

ECU Health Medical Center
Greenville 4469160, North Carolina 4482348 27834
Contact:
Site Public Contact
252-744-2391
research@ecuhealth.org

Duke Women's Cancer Care Raleigh
Raleigh 4487042, North Carolina 4482348 27607
Contact:
Site Public Contact
919-785-4878

Novant Health New Hanover Regional Medical Center
Wilmington 4499379, North Carolina 4482348 28401
Contact:
Site Public Contact
910-342-3000

Wake Forest University Health Sciences
Winston-Salem 4499612, North Carolina 4482348 27157
Contact:
Site Public Contact
336-713-6771

Sanford Bismarck Medical Center
Bismarck 5688025, North Dakota 5690763 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Broadway Medical Center
Fargo 5059163, North Dakota 5690763 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Roger Maris Cancer Center
Fargo 5059163, North Dakota 5690763 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

UHHS-Chagrin Highlands Medical Center
Beachwood 5146711, Ohio 5165418 44122
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Aultman Health Foundation
Canton 5149222, Ohio 5165418 44710
Contact:
Site Public Contact
330-363-7274
ClinicalReserachDept@aultman.com

Miami Valley Hospital South
Centerville 4508204, Ohio 5165418 45459
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Geauga Hospital
Chardon 5149818, Ohio 5165418 44024
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Good Samaritan Hospital - Cincinnati
Cincinnati 4508722, Ohio 5165418 45220
Contact:
Site Public Contact
720-874-1881
ResearchInstituteInquiries@CommonSpirit.org

Case Western Reserve University
Cleveland 5150529, Ohio 5165418 44106
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

MetroHealth Medical Center
Cleveland 5150529, Ohio 5165418 44109
Contact:
Site Public Contact
216-778-7559
ababal@metrohealth.org

Ohio State University Comprehensive Cancer Center
Columbus 4509177, Ohio 5165418 43210
Contact:
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Miami Valley Hospital
Dayton 4509884, Ohio 5165418 45409
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Hospital North
Dayton 4509884, Ohio 5165418 45415
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Atrium Medical Center-Middletown Regional Hospital
Franklin 4512203, Ohio 5165418 45005-1066
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Cancer Care and Infusion
Greenville 5156493, Ohio 5165418 45331
Contact:
Site Public Contact
937-569-7515

UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor 5162645, Ohio 5165418 44060
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

ProMedica Flower Hospital
Sylvania 5173572, Ohio 5165418 43560
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

Upper Valley Medical Center
Troy 5174358, Ohio 5165418 45373
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

UH Seidman Cancer Center at Saint John Medical Center
Westlake 5176517, Ohio 5165418 44145
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

University of Oklahoma Health Sciences Center
Oklahoma City 4544349, Oklahoma 4544379 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Mercy Hospital Oklahoma City
Oklahoma City 4544349, Oklahoma 4544379 73120
Contact:
Site Public Contact
405-752-3402

Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa 4553433, Oklahoma 4544379 74146
Contact:
Site Public Contact
918-505-3200

Providence Newberg Medical Center
Newberg 5742726, Oregon 5744337 97132
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Legacy Good Samaritan Hospital and Medical Center
Portland 5746545, Oregon 5744337 97210
Contact:
Site Public Contact
800-220-4937
cancer@lhs.org

Providence Portland Medical Center
Portland 5746545, Oregon 5744337 97213
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Portland 5746545, Oregon 5744337 97225
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Oregon Health and Science University
Portland 5746545, Oregon 5744337 97239
Contact:
Site Public Contact
503-494-1080
trials@ohsu.edu

Legacy Meridian Park Hospital
Tualatin 5757506, Oregon 5744337 97062
Contact:
Site Public Contact
503-413-1742

Lehigh Valley Hospital-Cedar Crest
Allentown 5178127, Pennsylvania 6254927 18103
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Saint Luke's Cancer Center - Allentown
Allentown 5178127, Pennsylvania 6254927 18104
Contact:
Site Public Contact
610-776-4714

Saint Luke's University Hospital-Bethlehem Campus
Bethlehem 5180225, Pennsylvania 6254927 18015
Contact:
Site Public Contact
484-503-4151

Lehigh Valley Hospital - Muhlenberg
Bethlehem 5180225, Pennsylvania 6254927 18017
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Bryn Mawr Hospital
Bryn Mawr 5182063, Pennsylvania 6254927 19010
Contact:
Site Public Contact
484-476-2649
turzoe@mlhs.org

Pocono Medical Center
East Stroudsburg 5188075, Pennsylvania 6254927 18301
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Saint Luke's Hospital-Anderson Campus
Easton 5188140, Pennsylvania 6254927 18045
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Lehigh Valley Hospital-Hazleton
Hazleton 5193011, Pennsylvania 6254927 18201
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Riddle Memorial Hospital
Media 4559575, Pennsylvania 6254927 19063
Contact:
Site Public Contact
484-476-2649
turzoe@mlhs.org

Paoli Memorial Hospital
Paoli 5205037, Pennsylvania 6254927 19301
Contact:
Site Public Contact
484-476-2649
turzoe@mlhs.org

Pennsylvania Hospital
Philadelphia 4560349, Pennsylvania 6254927 19107
Contact:
Site Public Contact
855-216-0098
PennCancerTrials@careboxhealth.com

Thomas Jefferson University Hospital
Philadelphia 4560349, Pennsylvania 6254927 19107
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Fox Chase Cancer Center
Philadelphia 4560349, Pennsylvania 6254927 19111
Contact:
Site Public Contact
215-728-4790

Saint Luke's Hospital - Upper Bucks Campus
Quakertown 5207381, Pennsylvania 6254927 18951
Contact:
Site Public Contact
610-776-4714

Chester County Hospital
West Chester 4562144, Pennsylvania 6254927 19380
Contact:
Site Public Contact
610-431-5044
carolann.hoppes@pennmedicine.upenn.edu

Asplundh Cancer Pavilion
Willow Grove 5219619, Pennsylvania 6254927 19090
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Lankenau Medical Center
Wynnewood 5220230, Pennsylvania 6254927 19096
Contact:
Site Public Contact
484-476-2649
turzoe@mlhs.org

Women and Infants Hospital
Providence 5224151, Rhode Island 5224323 02905
Contact:
Site Public Contact
401-274-1122

Smilow Cancer Hospital Care Center - Westerly
Westerly 5225631, Rhode Island 5224323 02891
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Saint Joseph's/Candler - Bluffton Campus
Bluffton 4571722, South Carolina 4597040 29910
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Medical University of South Carolina
Charleston 4574324, South Carolina 4597040 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Avera Cancer Institute-Aberdeen
Aberdeen 5225857, South Dakota 5769223 57401
Contact:
Site Public Contact
605-622-8700
oncregulatory@avera.org

Sanford Cancer Center Oncology Clinic
Sioux Falls 5231851, South Dakota 5769223 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Avera Cancer Institute
Sioux Falls 5231851, South Dakota 5769223 57105
Contact:
Site Public Contact
605-322-3095
OncRegulatory@avera.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Dell Seton Medical Center at The University of Texas
Austin 4671654, Texas 4736286 78701
Contact:
Site Public Contact
512-324-7991

University of Texas at Austin
Austin 4671654, Texas 4736286 78712
Contact:
Site Public Contact
512-232-1543
irb@austin.utexas.edu

Tarrant County Hospital District/JPS Health Network
Fort Worth 4691930, Texas 4736286 76104
Contact:
Site Public Contact
817-702-5913
macosta02@jpshealth.org

UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth 4691930, Texas 4736286 76104
Contact:
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

Houston Methodist Hospital
Houston 4699066, Texas 4736286 77030
Contact:
Site Public Contact
713-790-2700

Methodist Willowbrook Hospital
Houston 4699066, Texas 4736286 77070
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Houston Methodist West Hospital
Houston 4699066, Texas 4736286 77094
Contact:
Site Public Contact
832-522-2873

Houston Methodist Saint John Hospital
Nassau Bay 4713813, Texas 4736286 77058
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UT Southwestern Clinical Center at Richardson/Plano
Richardson 4722625, Texas 4736286 75080
Contact:
Site Public Contact
972-669-7044
Suzanne.cole@utsouthwestern.edu

Houston Methodist Sugar Land Hospital
Sugar Land 4734825, Texas 4736286 77479
Contact:
Site Public Contact
281-242-2873

Houston Methodist The Woodlands Hospital
The Woodlands 4736476, Texas 4736286 77385
Contact:
Site Public Contact
713-790-2700
hmthewoodlands@houstonmethodist.org

Huntsman Cancer Institute/University of Utah
Salt Lake City 5780993, Utah 5549030 84112
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

South Jordan Health Center
South Jordan 5781770, Utah 5549030 84009
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Henrico Doctor's Hospital
Richmond 4781708, Virginia 6254928 23229
Contact:
Site Public Contact
804-591-4152

VCU Massey Cancer Center at Stony Point
Richmond 4781708, Virginia 6254928 23235
Contact:
Site Public Contact
ctoclinops@vcu.edu

VCU Massey Comprehensive Cancer Center
Richmond 4781708, Virginia 6254928 23298
Contact:
Site Public Contact
804-628-6430
CTOclinops@vcu.edu

Carilion Roanoke Memorial Hospital
Roanoke 4782167, Virginia 6254928 24033
Contact:
Site Public Contact
540-985-8510

Swedish Cancer Institute-Edmonds
Edmonds 5793427, Washington 5815135 98026
Contact:
Site Public Contact
206-215-2343
PCRC-NCORP@Swedish.org

Swedish Medical Center-First Hill
Seattle 5809844, Washington 5815135 98122
Contact:
Site Public Contact
206-215-2343
PCRC-NCORP@Swedish.org

Legacy Salmon Creek Hospital
Vancouver 5814616, Washington 5815135 98686
Contact:
Site Public Contact
503-413-2150

West Virginia University Charleston Division
Charleston 4801859, West Virginia 4826850 25304
Contact:
Site Public Contact
304-388-9944

West Virginia University Healthcare
Morgantown 4815352, West Virginia 4826850 26506
Contact:
Site Public Contact
304-293-7374
cancertrialsinfo@hsc.wvu.edu

Marshfield Medical Center-EC Cancer Center
Eau Claire 5251436, Wisconsin 5279468 54701
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Saint Vincent Hospital Cancer Center Green Bay
Green Bay 5254962, Wisconsin 5279468 54301
Contact:
Site Public Contact
920-433-8889
WI_research_admin@hshs.org

Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay 5254962, Wisconsin 5279468 54303
Contact:
Site Public Contact
920-433-8889
wi_research_admin@hshs.org

Gundersen Lutheran Medical Center
La Crosse 5258957, Wisconsin 5279468 54601
Contact:
Site Public Contact
608-775-2385
cancerctr@gundersenhealth.org

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison 5261457, Wisconsin 5279468 53718
Contact:
Site Public Contact
800-622-8922
clinicaltrials@cancer.wisc.edu

University of Wisconsin Carbone Cancer Center - University Hospital
Madison 5261457, Wisconsin 5279468 53792
Contact:
Site Public Contact
800-622-8922
clinicaltrials@cancer.wisc.edu

Marshfield Medical Center-Marshfield
Marshfield 5261969, Wisconsin 5279468 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Medical College of Wisconsin
Milwaukee 5263045, Wisconsin 5279468 53226
Contact:
Site Public Contact
414-805-3666

Marshfield Medical Center - Minocqua
Minocqua 5263156, Wisconsin 5279468 54548
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

ProHealth D N Greenwald Center
Mukwonago 5263965, Wisconsin 5279468 53149
Contact:
Site Public Contact
research.institute@phci.org

Cancer Center of Western Wisconsin
New Richmond 5264475, Wisconsin 5279468 54017
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

ProHealth Oconomowoc Memorial Hospital
Oconomowoc 5265499, Wisconsin 5279468 53066
Contact:
Site Public Contact
262-928-7878

Saint Vincent Hospital Cancer Center at Oconto Falls
Oconto Falls 5265522, Wisconsin 5279468 54154
Contact:
Site Public Contact
920-433-8889
WI_research_admin@hshs.org

Marshfield Medical Center-Rice Lake
Rice Lake 5268798, Wisconsin 5279468 54868
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Saint Vincent Hospital Cancer Center at Sheboygan
Sheboygan 5272893, Wisconsin 5279468 53081
Contact:
Site Public Contact
920-433-8889
wi_research_admin@hshs.org

Sheboygan Physicians Group
Sheboygan 5272893, Wisconsin 5279468 53081
Contact:
Site Public Contact
920-433-8889
wi_research_admin@hshs.org

Marshfield Medical Center-River Region at Stevens Point
Stevens Point 5274644, Wisconsin 5279468 54482
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Contact:
Site Public Contact
920-433-8889
wi_research_admin@hshs.org

UW Cancer Center at ProHealth Care
Waukesha 5278052, Wisconsin 5279468 53188
Contact:
Site Public Contact
262-928-5539
Chanda.miller@phci.org

Marshfield Medical Center - Weston
Weston 5278693, Wisconsin 5279468 54476
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Centro Comprensivo de Cancer de UPR
San Juan 4568127, Puerto Rico 00927
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

More Details

NCT ID
NCT05256225
Status
Recruiting
Sponsor
National Cancer Institute (NCI)

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer. SECONDARY OBJECTIVES: I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer. II. To evaluate the overall response rate (ORR) in patients with measurable disease. III. To evaluate the duration of objective response in patients with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0 for each treatment arm. V. To compare quality of life (QOL), as measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En-TOI), in the experimental versus control arms. VI. To compare patient-reported treatment-associated symptoms (diarrhea and rash) as measured with the Patient Reported Outcomes (PRO) - CTCAE, patient-reported fatigue as measured with the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue short form, and worry concerning side effects of treatment as measured by the item 'bothered by side effect', in the FACT-En TOI, respectively, in the experimental and control arms. VII. To assess the correlation of HER2 immunohistochemistry (IHC) expression and in situ hybridization (ISH) amplification with clinical outcome and response to HER2 targeted therapies. EXPLORATORY OBJECTIVE: I. To explore time to sustained deterioration in quality of life, as measured by a drop in the FACT-En-TOI by 6 or more points lasting for more than one PRO time point, in the experimental and control arms. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. ARM II: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk subcutaneously (SC) over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment. ARM III: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician. MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and computed tomography (CT) throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.